Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

被引：10

作者：

Cortellini, Alessio ^{[1
,2
]}

Buti, Sebastiano ^{[3
]}

Bersanelli, Melissa ^{[3
,4
]}

Giusti, Raffaele ^{[5
]}

Perrone, Fabiana ^{[3
]}

Di Marino, Pietro ^{[6
]}

Tinari, Nicola ^{[7
]}

De Tursi, Michele ^{[7
]}

Grassadonia, Antonino ^{[7
]}

Cannita, Katia ^{[1
]}

Tessitore, Alessandra ^{[2
]}

Zoratto, Federica ^{[8
]}

Veltri, Enzo ^{[8
]}

Malorgio, Francesco ^{[9
]}

Russano, Marco ^{[10
]}

Anesi, Cecilia ^{[10
]}

Zeppola, Tea ^{[10
]}

Filetti, Marco ^{[5
]}

Marchetti, Paolo ^{[5
,11
,12
,13
]}

Botticelli, Andrea ^{[11
]}

Cappellini, Gian Carlo Antonini ^{[13
]}

De Galitiis, Federica ^{[13
]}

Vitale, Maria Giuseppa ^{[14
]}

Rastelli, Francesca ^{[15
]}

Pergolesi, Federica ^{[15
]}

Berardi, Rossana ^{[16
]}

Rinaldi, Silvia ^{[16
]}

Tudini, Marianna ^{[17
]}

Silva, Rosa Rita ^{[17
]}

Pireddu, Annagrazia ^{[18
]}

Atzori, Francesco ^{[18
]}

Iacono, Daniela ^{[19
]}

Migliorino, Maria Rita ^{[19
]}

Gelibter, Alain ^{[12
]}

Occhipinti, Mario Alberto ^{[12
]}

Martella, Francesco ^{[12
]}

Inno, Alessandro ^{[20
]}

Gori, Stefania ^{[21
]}

Bracarda, Sergio ^{[21
]}

Zannori, Cristina ^{[22
]}

Mosillo, Claudia ^{[22
]}

Parisi, Alessandro ^{[1
,2
]}

Porzio, Giampiero ^{[1
,2
]}

Mallardo, Domenico ^{[23
]}

Fargnoli, Maria Concetta ^{[2
,24
]}

Tiseo, Marcello ^{[3
,4
]}

Santini, Daniele ^{[10
]}

Ascierto, Paolo A. ^{[23
]}

Ficorella, Corrado ^{[1
,2
]}

机构：

[1] St Salvatore Hosp, Med Oncol, Laquila, Italy

[2] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[3] Univ Hosp Parma, Med Oncol, Parma, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Azienda Osped Univ St Andrea, UOC Oncol Med, Rome, Italy

[6] SS Annunziata Hosp, Clin Oncol Unit, Chieti, Italy

[7] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[8] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[9] Santo Spirito Hosp, Med Oncol, Pescara, Italy

[10] Campus Biomed Univ, Med Oncol, Rome, Italy

[11] Sapienza Univ Rome, Med Oncol, Rome, Italy

[12] Policlin Umberto 1, Med Oncol B, Rome, Italy

[13] IDI IRCCS, Med Oncol, Rome, Italy

[14] Univ Hosp Modena, Med Oncol, Modena, Italy

[15] Fermo Area Vasta 4, Med Oncol, Fermo, Italy

[16] Univ Politecn Marche, Oncol Clin, Ancona, Italy

[17] AV2 Fabriano ASUR Marche, Med Oncol, Fabriano, Italy

[18] Univ Hosp Cagliari, Med Oncol Unit, Cagliari, Italy

[19] St Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[20] G Mazzini Hosp, Med Oncol, Teramo, Italy

[21] Sacro Cuore Don Calabria Hosp, Med Oncol Unit, IRCCS, Verona, Italy

[22] Azienda Osped S Maria, Med Oncol, Terni, Italy

[23] IRCCS Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Ist Nazl Tumori, Naples, Italy

[24] San Salvatore Hosp, Dermatol, Laquila, Italy

来源：

ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期

关键词：

Family history of cancer; multiple neoplasms; DDR genes; immune checkpoint inhibitors; immunotherapy; PD-1; CELL LUNG-CANCER; DNA-DAMAGE RESPONSE; ADVERSE EVENTS; ELDERLY-PATIENTS; PD-1; BLOCKADE; ASSOCIATION; NIVOLUMAB; TUMORS; MELANOMA; GENES;

D O I：

10.1080/2162402X.2019.1710389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer diagnoses in only one family line), and FHC-negative. Patients were also categorized according to the diagnosis of MN as follows: MN-high (>2 malignancies), MN-low (two malignancies), and MN-negative. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of immune-related adverse events (irAEs) of any grade were evaluated. Results: 822 consecutive patients were evaluated. 458 patients (55.7%) were FHC-negative, 289 (35.2%) were FHC-low, and 75 (9.1%) FHC-high, respectively. 29 (3.5%) had a diagnosis of synchronous MN and 94 (11.4%) of metachronous MN. 108 (13.2%) and 15 (1.8%) patients were MN-low and MN-high, respectively. The median follow-up was 15.6 months. No significant differences were found regarding ORR among subgroups. FHC-high patients had a significantly longer PFS (hazard ratio [HR] = 0.69 [95% CI: 0.48-0.97], p = .0379) and OS (HR = 0.61 [95% CI: 0.39-0.93], p = .0210), when compared to FHC-negative patients. FHC-high was confirmed as an independent predictor for PFS and OS at multivariate analysis. No significant differences were found according to MN categories. FHC-high patients had a significantly higher incidence of irAEs of any grade, compared to FHC-negative patients (p = .0012). Conclusions: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors.

引用

页数：10

共 38 条

[1]

[Anonymous], 2013, Sturdivant RX. Applied Logistic Regression

[2]

[Anonymous], INT AGENCY RES CANC

[3] Trends in kidney cancer among the elderly in Denmark, 1980-2012 [J].

Azawi, Nessn H. ;

Joergensen, Simon Moeller ;

Jensen, Niels Viggo ;

Clark, Peter E. ;

Lund, Lars .

ACTA ONCOLOGICA, 2016, 55 :79-84

[4] Distinctive Features of Melanoma and Its Management in Elderly Patients A Population-Based Study in France [J].

Ciocan, Dragos ;

Barbe, Coralie ;

Aubin, Francois ;

Granel-Brocard, Florence ;

Lipsker, Dan ;

Velten, Michel ;

Dalac, Sophie ;

Truchetet, Francois ;

Michel, Catherine ;

Mitschler, Audrey ;

Arnoult, Gwendoline ;

Buemi, Antoine ;

Dalle, Stephane ;

Bernard, Philippe ;

Woronoff, Anne-Sophie ;

Grange, Florent .

JAMA DERMATOLOGY, 2013, 149 (10) :1150-1157

[5] Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients [J].

Cortellini, Alessio ;

Chiari, Rita ;

Ricciuti, Biagio ;

Metro, Giulio ;

Perrone, Fabiana ;

Tiseo, Marcello ;

Bersanelli, Melissa ;

Bordi, Paola ;

Santini, Daniele ;

Giusti, Raffaele ;

Grassadonia, Antonino ;

Di Marino, Pietro ;

Tinari, Nicola ;

De Tursi, Michele ;

Zoratto, Federica ;

Veltri, Enzo ;

Malorgio, Francesco ;

Garufi, Carlo ;

Russano, Marco ;

Anesi, Cecilia ;

Zeppola, Tea ;

Filetti, Marco ;

Marchetti, Paolo ;

Berardi, Rossana ;

Rinaldi, Silvia ;

Tudini, Marianna ;

Silva, Rosa Rita ;

Pireddu, Annagrazia ;

Atzori, Francesco ;

Iacono, Daniela ;

Migliorino, Maria Rita ;

Porzio, Gampiero ;

Cannita, Katia ;

Ficorella, Corrado ;

Buti, Sebastiano .

CLINICAL LUNG CANCER, 2019, 20 (04) :237-+

[6] A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable [J].

Cortellini, Alessio ;

Bersanelli, Melissa ;

Buti, Sebastiano ;

Cannita, Katia ;

Santini, Daniele ;

Perrone, Fabiana ;

Giusti, Raffaele ;

Tiseo, Marcello ;

Michiara, Maria ;

Di Marino, Pietro ;

Tinari, Nicola ;

De Tursi, Michele ;

Zoratto, Federica ;

Veltri, Enzo ;

Marconcini, Riccardo ;

Malorgio, Francesco ;

Russano, Marco ;

Anesi, Cecilia ;

Zeppola, Tea ;

Filetti, Marco ;

Marchetti, Paolo ;

Botticelli, Andrea ;

Cappellini, Gian Carlo Antonini ;

De Galitiis, Federica ;

Vitale, Maria Giuseppa ;

Rastelli, Francesca ;

Pergolesi, Federica ;

Berardi, Rossana ;

Rinaldi, Silvia ;

Tudini, Marianna ;

Silva, Rosa Rita ;

Pireddu, Annagrazia ;

Atzori, Francesco ;

Chiari, Rita ;

Ricciuti, Biagio ;

De Giglio, Andrea ;

Iacono, Daniela ;

Gelibter, Alain ;

Occhipinti, Mario Alberto ;

Parisi, Alessandro ;

Porzio, Giampiero ;

Fargnoli, Maria Concetta ;

Ascierto, Paolo Antonio ;

Ficorella, Corrado ;

Natoli, Clara .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[7] Family history of cancer and DNA damage response genes: Two sides of the same coin? [J].

Cortellini, Alessio ;

Bersanelli, Melissa ;

Ficorella, Corrado ;

Buti, Sebastiano .

THORACIC CANCER, 2019, 10 (02) :401-401

[8] Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study [J].

Cortellini, Alessio ;

Bersanelli, Melissa ;

Buti, Sebastiano ;

Gambale, Elisabetta ;

Atzori, Francesco ;

Zoratto, Federica ;

Parisi, Alessandro ;

Brocco, Davide ;

Pireddu, Annagrazia ;

Cannita, Katia ;

Iacono, Daniela ;

Migliorino, Maria R. ;

Gamucci, Teresa ;

De Tursi, Michele ;

Sidoni, Tina ;

Tiseo, Marcello ;

Michiara, Maria ;

Papa, Anselmo ;

Angius, Gesuino ;

Tomao, Silverio ;

Fargnoli, Maria C. ;

Natoli, Clara ;

Ficorella, Corrado .

IMMUNOTHERAPY, 2018, 10 (08) :643-655

[9]

COX DR, 1972, J R STAT SOC B, V34, P187

[10] Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma [J].

Dai, Ying ;

Sun, Chengdu ;

Feng, Yi ;

Jia, Qingzhu ;

Zhu, Bo .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22 (08) :3979-3986

← 1 2 3 4 →